about
Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularizationAnti-vascular endothelial growth factor acts on retinal microglia/macrophage activation in a rat model of ocular inflammationProstate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization.Integration of drug, protein, and gene delivery systems with regenerative medicine.Intravitreal Ranibizumab for Stage IV Proliferative Sickle Cell Retinopathy: A First Case Report.Serum MicroRNAs as Potential Biomarkers of AMDDaily Optical Coherence Tomography Examinations after First Antivascular Endothelial Growth Factor Injections: An Interventional Case Series.Efficacy of Ethanol Extract of Fructus lycii and Its Constituents Lutein/Zeaxanthin in Protecting Retinal Pigment Epithelium Cells against Oxidative Stress: In Vivo and In Vitro Models of Age-Related Macular DegenerationRanibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study.The Pharmacological Effects of Lutein and Zeaxanthin on Visual Disorders and Cognition Diseases.Prevalence of Age-Related Macular Degeneration in Slovakia and Associated Risk Factors: A Mobile Clinic-Based Cross-Sectional Epidemiological Survey.HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.Intravitreal aflibercept for neovascular age-related macular degeneration.[Treatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme].
P2860
Q28582445-8CB7A41B-D8C1-452E-84E1-FE6C1DBDCFE1Q33793109-6DC49923-7980-42DC-871C-076B64E44004Q34345914-B76B3227-D579-499C-9A0E-6A36FF2164D1Q35241569-8D6D5A55-15FA-4E50-BB16-CF4310E3D6B9Q35519205-F4EFA757-F0AB-484F-BC23-B70F7151159DQ36078404-9D8D3784-BC45-4F3F-9A00-98657A698CB7Q36914264-2B3F4B39-EFA8-4A59-A446-F01B80D537FBQ37218617-72BB47BC-6FDC-46DD-A944-F61DA7073837Q38094076-FF3F2363-DC0D-4BAC-B779-EC2B02E51BA2Q38680981-7274ED5C-70FF-4F73-9137-4BAE6B372D3AQ38692816-52F2DD08-286E-44AD-851F-4224097B5123Q38775043-8F352284-A23B-4210-81C5-AA82732D038EQ38825960-7E9ABD5F-DF54-447E-A843-C6DA8783905BQ39466620-E67CBCBD-864C-41EF-8684-BF84F2A9000CQ44116864-2CF2CBFC-A520-48F0-B4FE-A1CAEB9BEA12
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Ranibizumab for age-related macular degeneration.
@en
Ranibizumab for age-related macular degeneration.
@nl
type
label
Ranibizumab for age-related macular degeneration.
@en
Ranibizumab for age-related macular degeneration.
@nl
prefLabel
Ranibizumab for age-related macular degeneration.
@en
Ranibizumab for age-related macular degeneration.
@nl
P2860
P1476
Ranibizumab for age-related macular degeneration
@en
P2093
Dilsher S Dhoot
P2860
P304
P356
10.1517/14712598.2012.660523
P407
P577
2012-02-06T00:00:00Z